Skip to main content
Home Report Heatmap Pricing Get Started
Home / Heatmap / JNJ
JNJ

Johnson & Johnson — Beer Score

JNJ · US Equity · Healthcare — Pharmaceuticals
$162.00
Market Price (indicative) · Feb 7, 2026
+$0.45 (+0.28%) today
Reference price only. Not an official exchange feed.
87
/ 100
Solid Value — Est. 87% Fundamental Value
Updated: Feb 7, 2026 16:30 UTC·Filing: 10-K (Jan 29, 2026)·Model: DCF v1.0
Not investment advice · Model-based estimate
Estimated Value (Beer)
$140.94
87%
Est. Speculation Premium (Foam)
$21.06
13%
🍺 87% Est. Fundamental Value🫧 13% Est. Speculation
Track Score Alerts (Pro) See Model Assumptions ↓

Key Financials

TTM
Revenue$85.2B
Net Income$14.6B
Free Cash Flow$18.0B
P/E Ratio22.4x
EPS (TTM)$7.23
Market Cap$390B
Total Debt$29.8B
Cash & Equiv.$14.7B

DCF Valuation

Model Estimate
$140
Est. intrinsic value (DCF model)
vs $162.00 market price
↓
Our model suggests the current price is ~15% above the estimated intrinsic value. The market may be pricing in growth beyond current fundamentals.
WACC7.5%
Growth Rate (5yr)4%
Terminal Growth2.5%
Margin of Safety~−15%

Model output varies with assumptions (WACC, growth, margins). This is not a price target or investment recommendation.

Score History — 90 Days

Pro
90d Low
84
90d High
89
Zone Changes
1
▸_
Unlock Full Score HistoryAlerts · Chart export · Peer compare

J&J Stock Valuation — Beer Score Breakdown

J&J's Beer Score of 87 means that, according to our DCF model, the stock is well-supported by fundamentals. An estimated 87% of the stock price is backed by earnings, cash flow, and assets.

How Beer Score Is Calculated for JNJ

We pull J&J's latest SEC filings from EDGAR, run a DCF analysis using a 7.5% WACC and 4% revenue growth rate over 5 years with 2.5% terminal growth, then compare the resulting model estimate ($140) against the current market price ($162.00). The Beer Score of 87 represents the ratio. Model output varies with assumptions. Learn more about our methodology →

Important Information

Beer Score is an educational indicator, not investment advice. It measures the model-estimated gap between a stock's current market price and an estimated intrinsic value derived from public financial data. A low Beer Score does not mean "sell" and a high score does not mean "buy." Model output varies with assumptions (WACC, growth rate, terminal growth, margins).

Prices shown are indicative reference prices for educational purposes only and are not sourced from an official exchange feed. Data sources include SEC EDGAR filings, indicative market price data, and proprietary DCF models. Scores update daily after market close. For the full ranking of all 45 stocks, visit the Beer Score Heatmap or read Today's Foam Report.

Track J&J's Beer Score Over Time

Get daily score changes, alerts when foam levels shift, and full history charts with Pro.

See Pro Plans → View All 45 Stocks

About This Valuation

Why does J&J have a Beer Score of 58?
J&J (JNJ) scores 58 because the stock is currently trading roughly 74% above its estimated intrinsic value of $140. With $18.0B in annual free cash flow and $85.2B in revenue, the company's fundamentals partially justify the current market price of $243.45 per share. The Beer Score reflects that 58% of the price is backed by estimated fundamental value.
Is JNJ overvalued or undervalued?
Based on our DCF model, J&J appears moderately overvalued. The estimated intrinsic value of $140 compared to the current price of $243.45 carries a 42% speculation premium. This is a model-based estimate using 7.5% WACC and 4% projected growth — not a buy or sell recommendation. The actual fair value depends on assumptions that may change with new earnings data or market conditions.
What assumptions drive the $140 intrinsic value?
The DCF model uses a 7.5% weighted average cost of capital and projects 4% annual revenue growth over five years. Terminal growth is set at 2.5%. Starting from $18.0B in current free cash flow, these assumptions produce an estimated intrinsic value of $140 per share. The model is most sensitive to the growth rate and WACC inputs — small changes in either significantly alter the output.
What could change J&J's Beer Score?
J&J's score depends on pharmaceutical pipeline execution after the Kenvue consumer health spinoff. Patent cliffs on key drugs like Stelara create near-term revenue headwinds. Talc litigation reserves could require additional charges. MedTech demand recovery and successful launches of new oncology and immunology drugs could push intrinsic value higher over the next two years.

Compare Similar Stocks

PFE83 DHR94 UNH100 LLY17
View all stock valuations →